WO2026008836 - GLP-1 DERIVATIVES AND USES THEREOF
National phase entry is expected:
Publication Number
WO/2026/008836
Publication Date
08.01.2026
International Application No.
PCT/EP2025/069132
International Filing Date
04.07.2025
Title **
[English]
GLP-1 DERIVATIVES AND USES THEREOF
[French]
DÉRIVÉS DE GLP-1 ET LEURS UTILISATIONS
Applicants **
NOVO NORDISK A/S
Inventors
LINDEROTH, Lars
REEDTZ-RUNGE, Steffen
WALDHOER, Maria
KOFOED, Jacob
Priority Data
24186705.0
05.07.2024
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2194 | |
| EPO | Filing, Examination, Granting | 8791 | |
| Japan | Filing, Examination, Granting | 2161 | |
| South Korea | Filing, Examination, Granting | 2056 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
19,942
Contact Us
Abstract[English]
The present invention relates to novel GLP-1 derivatives that are activating the GLP- 1 receptor in a way that favours a cAMP response and has an impaired beta-arrestin recruitment. More particular the present invention relates to such GLP-1 derivatives and their use for treatment of diseases such as diabetes and obesity.[French]
La présente invention concerne de nouveaux dérivés de GLP-1 qui activent le récepteur GLP-1 d'une manière qui favorise une réponse cAMP et a un recrutement de bêta-arrestine altéré. Plus particulièrement, la présente invention concerne de tels dérivés de GLP-1 et leur utilisation pour le traitement de maladies telles que le diabète et l'obésité.